Erlotinib

Category: pharmacological

Aliases: Tarceva

Pharmacological Mechanism

EGFR tyrosine kinase inhibitor — competitive ATP-site blockade. First-line therapy for EGFR-mutant non-small-cell lung cancer. CYP3A4 substrate. Acneiform rash (~75%) correlates with response. Smoking induces CYP1A2-mediated clearance, lowering levels.

Half-Life (t½)

PO: 36h

Dosing Guidelines

• PO: Typical 150mg (Range: 100 - 150 mg)

Target Organ Systems

• respiratory
• digestive